US pharmaceutical giant Eli Lilly is betting big on AI-driven drug development, signing a $2.75 billion deal with Hong Kong-listed Insilico Medicine. The article Eli Lilly signs $2.75 billion deal with AI drug developer Insilico Medicine appeared first on The Decoder.
